A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation

Zhan, Yongle; Zhang, Bin; Zhou, Yanling; Zheng, Wei; Liu, Weijian; Wang, Chengyu; Li, Hanqiu; Chen, Lijian; Lin, Yongcheng; Walter, Martin; Lv, Meng; Li, Ming D.; Ning, Yuping

doi:10.1016/j.jad.2019.03.071

Cited by 47 publications

(31 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Response and remission were defined as at least 50% reduction from the baseline HAMD-17 scores and HAMD-17 scores ≤7, respectively, following the methodology of a prior study. 21…”

Section: Clinical Assessmentmentioning

confidence: 99%

BDNF and the Antidepressant Effects of Ketamine and Propofol in Electroconvulsive Therapy: A Preliminary Study

Huang¹,

Xiong²,

He³

et al. 2020

NDT

Self Cite

View full text Add to dashboard Cite

Objective: Ketamine and propofol have become increasingly popular in electroconvulsive therapy (ECT) anaesthesia. This study was conducted to examine whether changes in serum levels of brain-derived neurotrophic factor (BDNF) are associated with the antidepressant effects of ketofol, a combination of ketamine and propofol, in ECT for patients with treatment-resistant depression (TRD). Methods: Thirty patients with TRD (18-65 years) were enrolled and underwent eight ECT sessions with ketamine (0.5 mg/kg) plus propofol (0.5 mg/kg) (ketofol). Symptom severity was monitored using the 17-item Hamilton Depression Rating Scale (HAMD-17) and the Brief Psychiatric Rating Scale (BPRS), and serum levels of BDNF were examined by enzyme-linked immunosorbent assay (ELISA) at baseline and after 2, 4, and 8 ECT treatments. Serum levels of BDNF were also collected from thirty healthy controls. Results: At baseline, there were no significant differences in serum levels of BDNF between patients with TRD and healthy controls. The response and remission rates in patients with TRD were 100% (30/30) and 53.3% (16/30) after ECT treatment, respectively. Despite a significant reduction in HAMD-17 and BPRS scores after ECT, no changes in serum levels of BDNF were observed after ECT treatment when compared to baseline. No association was found between serum levels of BDNF and changes in illness severity. Conclusion: Serum levels of BDNF did not represent a suitable candidate biomarker for determining the antidepressant effects of ketofol during ECT for patients with TRD.

show abstract

“…Response and remission were defined as at least 50% reduction from the baseline HAMD-17 scores and HAMD-17 scores ≤7, respectively, following the methodology of a prior study. 21…”

Section: Clinical Assessmentmentioning

confidence: 99%

BDNF and the Antidepressant Effects of Ketamine and Propofol in Electroconvulsive Therapy: A Preliminary Study

Huang¹,

Xiong²,

He³

et al. 2020

NDT

Self Cite

View full text Add to dashboard Cite

show abstract

“…3 How long the beneficial effects of repeated ketamine last once infusions are stopped, however, remains largely unknown. With a few exceptions, 4,5 most clinical trials have not followed patients beyond a short period of time after trial completion. This has perhaps obscured inadvertent, negative sequelae that may emerge in the weeks and months after ketamine cessation.…”

Section: Introductionmentioning

confidence: 99%

Ketamine for chronic depression: two cautionary tales

Talbot

Phillips

Blier

2019

JPN

View full text Add to dashboard Cite

“…35 Such a rapid antisuicidal effect is in stark contrast to the delayed onset of currently available pharmacological treatment A recent open-label clinical trial that administered six intravenous doses of 0.5 mg/kg ketamine three times a week in patients with unipolar and bipolar depression reported a significant reduction in suicidal ideation 24 h after the first infusion in 57% of patients and in 65% after the sixth infusion. 36 The antisuicidal mechanism of ketamine remains speculative. Plasma kynurenine levels have been implicated in the pathophysiology of suicidal behavior, 37 and it has been suggested that ketamine may play a role in their modification.…”

Section: Multiple Administrationmentioning

confidence: 99%

Ketamine in Bipolar Disorder: A Review

Wilkowska¹,

Szałach²,

Cubała³

2020

NDT

View full text Add to dashboard Cite

Bipolar disorder (BD) is a psychiatric illness associated with high morbidity, mortality and suicide rate. It has neuroprogressive course and a high rate of treatment resistance. Hence, there is an unquestionable need for new BD treatment strategies. Ketamine appears to have rapid antidepressive and antisuicidal effects. Since most of the available studies concern unipolar depression, here we present a novel insight arguing that ketamine might be a promising treatment for bipolar disorder.

show abstract

A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation

Cited by 47 publications

References 40 publications

<p>BDNF and the Antidepressant Effects of Ketamine and Propofol in Electroconvulsive Therapy: A Preliminary Study</p>

<p>BDNF and the Antidepressant Effects of Ketamine and Propofol in Electroconvulsive Therapy: A Preliminary Study</p>

Ketamine for chronic depression: two cautionary tales

<p>Ketamine in Bipolar Disorder: A Review</p>

Contact Info

Product

Resources

About